ClinicalTrials.gg
RecruitingNCT05406999Updated Aug 16, 2022

Neoadjuvant Intense Endocrine Therapy for High Risk and Locally Advanced Prostate Cancer

A Phase 2 interventional study of ADT and Abiraterone Acetate in Neoadjuvant Therapy, High Risk Prostate Cancer and Locally Advanced Prostate Cancer, sponsored by The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School. Recruiting at 1 site in China. Open to male participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2022-08-16.

Sponsored by The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School · Phase 2, Interventional, and Treatment

How we know · 9 judgments

From the registry’s dates

  • Registered 2 years 3 months after the study started (first participant enrolled Feb 2020, registered May 2022).
  • Started Feb 2020; still recruiting 6 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
900
Allocation
Non-randomized
Ages
18 Years to 80 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 98 studies testing Abiraterone Acetate in Prostatic Neoplasms — 12 open to participants now, 29 under way, 4 of them phase 3. Abiraterone Acetate · Prostatic Neoplasms.

Planned enrollment
6th of 98
900 · median 56
Started
2020
with 10 others
Phase 2
59 of 98
9 open now
Primary completion
2026-12
later than 11 of 28 live
Registered
89th of 98
by date

Among the 98 studies testing Abiraterone Acetate in Prostatic Neoplasms, this one is the 6th largest by planned enrollment, is one of 11 that started in 2020, is one of 59 in phase 2, reaches primary completion later than 11 of the 28 other live ones, and was the 89th registered.

Prostatic Neoplasms

7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

12 of the 98 studies testing Abiraterone Acetate in Prostatic Neoplasms are open now, in 8 countries. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 12 open studies →

About Abiraterone Acetate

Abiraterone Acetate: first FDA approval 2011 (ZYTIGA), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years to 80 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 98 studies testing Abiraterone Acetate in Prostatic Neoplasms, or all of them as a file.
02

Study summary

This is a prospective, multicenter, multi-arm, non-randomized, open-label clinical trial to evaluate the efficacy and safety of neoadjuvant intense endocrine therapy for high-risk or locally advanced prostate cancer.

Read the detailed description

The study was designed to evaluate the efficacy and safety of different forms of neoadjuvant intense androgen deprivation therapy (ADT) compared with ADT alone, followed by prostatectomy.

03

Conditions studied

  • Neoadjuvant Therapy
  • High Risk Prostate Cancer
  • Locally Advanced Prostate Cancer
  • Intense Endocrine Therapy

Browse trials for

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. All patients must have been diagnosed of prostate cancer and must be eligible for radical prostatectomy.
  2. All patients must undergo thorough tumor staging and meet one of the following criteria: a) multi-parameter MRI or PSMA PET/CT shows clinical staging of primary tumor ≥ T3; b) Gleason score of primary tumor ≥ 8; c)prostate specific antigen(PSA) ≥20 ng/ml; d) Imaging evaluation shows regional lymph node (N1).
  3. (ECOG) physical condition score ≤ 1.
  4. Patients must have adequate hematologic function, hepatic function, renal function and cardiac function.
  5. Patients must participate voluntarily and sign an form(ICF), indicating that they understand the purpose and required procedures of the study, and are willing to participate in. Patients must bewilling to obey the prohibitions and restrictions specified in the research protocol.
  6. Fertile patients must be willing to use highly effective during the study period and within 120 days of the last dose of treatment.

Exclusion criteria

Exclusion Criteria:

  1. Patients with neuroendocrine, small cell, or sarcoma-like pathologic features are not eligible.
  2. Patients with low-risk or medium-risk, localized prostate cancer (the following conditions are met at the same time) are not eligible: a) multiparameter MRI or PSMA PET / CT shows clinical staging of primary tumor \< T3; b) Gleason score of primary tumor \< 8; c) prostate specific antigen (PSA) \<20 ng/ml.
  3. Patients with clinical or radiological evidence of extra-regional lymph node or bone metastases or visceral metastases (any M1) are not eligible.
  4. Patients who have previously received androgen deprivation therapy (medical or surgical) or focal treatment, radiotherapy, chemotherapy for prostate cancer are not eligible.
  5. Patients with severe or uncontrolled concurrent infections are not eligible.
  6. Patients must not have Class III or IV congestive heart failure at the time of screening. Patients must not have any thromboembolic event, unstable angina pectoris, myocardial infarction within 6 months prior to registration.
  7. Patients must not have uncontrolled severe hypertension, persistent uncontrolled diabetes, oxygen-dependent lung disease, chronic liver disease, or infection.
  8. Patients must not have had other other than prostate cancer in the past 5 years, but cured basal cell or squamous cell skin cancers can be enrolled.
  9. Patients with mental illness, mental disability or inability to give are not eligible.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
900 participants (estimated)

Study arms

  • Active comparator
    ADT alone + prostatectomy

    A total of 100 subjects receive ADT for 6 cycles (28 days per cycle) before prostatectomy. Robot-assisted radical prostatectomy was performed within 2 weeks after the end of the therapy.

    Drug: ADT · Procedure: Robot-assisted radical prostatectomy

  • Experimental
    ADT plus Abiraterone

    A total of 150 subjects in this group received abiraterone acetate + prednisolone acetate daily for 6 cycles along with ADT. Robot-assisted radical prostatectomy was performed within 2 weeks after the end of the therapy.

    Drug: ADT · Drug: Abiraterone Acetate · Drug: Prednisolone tablets · Procedure: Robot-assisted radical prostatectomy

  • Experimental
    ADT plus Enzalutamide

    A total of 50 subjects in this group received enzalutamide daily for 6 cycles along with ADT. Robot-assisted radical prostatectomy was performed within 2 weeks after the end of the therapy.

    Drug: ADT · Drug: Enzalutamide · Procedure: Robot-assisted radical prostatectomy

  • Experimental
    ADT plus Apalutamide

    A total of 150 subjects in this group received apalutamide daily for 6 cycles along with ADT. Robot-assisted radical prostatectomy was performed within 2 weeks after the end of the therapy.

    Drug: ADT · Drug: Apalutamide · Procedure: Robot-assisted radical prostatectomy

  • Experimental
    ADT plus Darotamide

    A total of 150 subjects in this group received darotamide daily for 6 cycles along with ADT. Robot-assisted radical prostatectomy was performed within 2 weeks after the end of the therapy.

    Drug: ADT · Drug: Darotamide · Procedure: Robot-assisted radical prostatectomy

  • Experimental
    ADT plus Rizvilutamide

    A total of 150 subjects in this group received rizvilutamide daily for 6 cycles along with ADT. Robot-assisted radical prostatectomy was performed within 2 weeks after the end of the therapy.

    Drug: ADT · Drug: Rezvilutamide · Procedure: Robot-assisted radical prostatectomy

  • Experimental
    PARP inhibitor + abiraterone + ADT

    A total of 100 subjects in this group received Poly ADP-ribose Polymerase (PARP) Inhibitor plus abiraterone along with ADT. Robot-assisted radical prostatectomy was performed within 2 weeks after the end of the therapy.

    Drug: ADT · Drug: Abiraterone Acetate · Drug: Prednisolone tablets · Drug: PARP inhibitor · Procedure: Robot-assisted radical prostatectomy

  • Experimental
    PARP inhibitor + ADT

    A total of 50 subjects in this group in this group received Poly ADP-ribose Polymerase (PARP) Inhibitor along with ADT mentioned above. Enrolled patients carry homologous recombination repair (HRR) gene mutation verified by molecular testing. Robot-assisted radical prostatectomy was performed within 2 weeks after the end of the therapy.

    Drug: ADT · Drug: PARP inhibitor · Procedure: Robot-assisted radical prostatectomy

Interventions

  • DrugAntiandrogensStudies of AntiandrogensAntiandrogens pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    The ADT regimen will be determined by the investigators at separate centers. The dose and frequency of administration will be consistent with the prescribing information. Available drugs include triptorelin, goserelin, leuprolide, digareke ect.

  • 1000 mg (250 mg×4 tablets) once daily, orally

  • DrugPrednisoloneStudies of PrednisolonePrednisolone pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    5 mg once daily, orally.

  • 160 mg (40 mg× 4 tablets) once daily, orally.

  • 240 mg (60 mg×4 tablets) once daily, orally.

  • DrugDarotamide

    600 mg (300 mg × 2 tablets) twice daily, orally.

  • 240 mg (80 mg × 3 tablets) once daily orally

  • DrugPARP inhibitorsStudies of PARP inhibitorsPARP inhibitors pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    The PARP inhibitors will be determined by the investigators at separate centers. The dosage and frequency of administration will be consistent with the prescribing information. Available drugs include olaparib, fluzoparib, pamiparib, talazoparib ect.

  • ProcedureRobot-assisted radical prostatectomy

    Robot-assisted radical prostatectomy was performed within 2 weeks after the end of the therapy.

This study also gives OlaparibStudies of OlaparibOlaparib pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. Pathologic response rate

    Pathologic response rate= Pathologic Complete Response (pCR) Rate + Minimal Residual Disease (MRD) rate

    Time frame: up to 3 years

  2. 3 year biochemical progression free survival (bPFS)

    Biochemical progression free survival (bPFS) within 3 years

    Time frame: up to 3 years

Secondary outcomes

  1. Metastasis-Free Survival (MFS)

    Metastasis-Free Survival (MFS) after intense neoadjuvant therapy

    Time frame: up to 5 years

  2. Time to castration-resistant prostate cancer(CRPC)

    Time to castration-resistant prostate cancer(CRPC) after intense neoadjuvant therapy

    Time frame: up to 5 years

  3. PSA response rate

    Prostate specific antigen (PSA) drops ≥ 98% after intense neoadjuvant therapy

    Time frame: up to 3 years

  4. Positive margin rate

    The positive margin rate of whole-mount pathology for prostatectomy after intense neoadjuvant therapy

    Time frame: up to 6 months

  5. Pathologic downgrade rate

    The pathologic downgrade rate of whole-mount pathology for prostatectomy after intense neoadjuvant therapy compared with initial T stage.

    Time frame: up to 6 months

  6. Number of participants with treatment-related adverse events as assessed by CTCAE v4.0

    Number of participants with treatment-related adverse events as assessed by CTCAE v4.0. All grades of adverse events will be documented.

    Time frame: up to 5 years

07

Study locations

1 of 1 sites recruiting
  • Department of Urology, Drum Tower Hospital, Medical School of Nanjing University, Institute of Urology, Nanjing University
    Nanjing, Jiangsu 210000, China
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2020 (actual). Primary completion is estimated for Dec 2026, 82 months after the start.

Of 613 non-industry phase 2 interventional studies under Prostatic Neoplasms, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 86. This study's planned 82 months is above that.

Counting every sponsor, half of 727 studies reached it within 53 months; a quarter within 34 and three quarters within 80.

How these figures are worked out, and which studies are left out of them.

Registered
May 29, 2022
First posted
Jun 7, 2022
StartActual
Feb 1, 2020
Primary completionEst.
Dec 31, 2026
CompletionEst.
Jun 30, 2030
Last update
Aug 16, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 16, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05406999
Responsible party
Hongqian Guo (Chief Physician, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School) — Principal investigator
First posted
Jun 7, 2022
Start date
Feb 1, 2020
Primary completion
Dec 31, 2026 (estimated)
Completion
Jun 30, 2030 (estimated)
Last update
Aug 16, 2022

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Abiraterone Acetate · Prednisolone · Enzalutamide · Apalutamide · Rezvilutamide · PARP inhibitors

Start the discussion